EVO-004

EVO-004 is a preclinical-stage therapeutic candidate being developed by Evozyne for the treatment of autoimmune diseases. The drug is engineered using Evozyne's proprietary evolutionary AI platform, which applies deep learning and high-throughput synthesis to design novel proteins with optimized functional properties. While the specific molecular target and modality (e.g., monoclonal antibody, cytokine trap, or enzyme) have not been publicly disclosed, the program represents Evozyne's expansion into the immunology space, leveraging its ability to create high-performance proteins that can modulate complex biological pathways.